RYBODYN SELECTED TO JOIN LILLY GATEWAY LABS TO ADVANCE NEXT-GEN IMMUNOTHERAPIES TARGETING THE DARK PROTEOME

RYBODYN SELECTED TO JOIN LILLY GATEWAY LABS TO ADVANCE NEXT-GEN IMMUNOTHERAPIES TARGETING THE DARK PROTEOME

Andrew Bass 6/19/25 Andrew Bass 6/19/25

RYBODYN SELECTED TO JOIN LILLY GATEWAY LABS TO ADVANCE NEXT-GEN IMMUNOTHERAPIES TARGETING THE DARK PROTEOME

Lilly Collaboration Accelerates RyboDyn’s Dark Proteome Targets Toward First-in-Class Therapies

RYBODYN EXPANDS STRATEGIC CANCER IMMUNOTHERAPY COLLABORATION WITH MOFFITT CANCER CENTER

Andrew Bass 5/15/25 Andrew Bass 5/15/25

RYBODYN EXPANDS STRATEGIC CANCER IMMUNOTHERAPY COLLABORATION WITH MOFFITT CANCER CENTER

RyboDyn Expands Strategic Cancer Immunotherapy Collaboration with Moffitt Cancer Center

RYBODYN ANNOUNCES DISCOVERY OF CRYPTIC HUMAN PROTEOME AND $4M PRE-SEED FINANCING

Andrew Bass 1/9/25 Andrew Bass 1/9/25

RYBODYN ANNOUNCES DISCOVERY OF CRYPTIC HUMAN PROTEOME AND $4M PRE-SEED FINANCING

RyboDyn, Inc. Announces Discovery of a Cryptic Human Proteome and $4M Pre-Seed Financing